Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 3, 2011, Pages 1140-1145

  Chen, Grace L ^a   Lau, Yuk Fai ^a,b   Lamirande, Elaine W ^a   McCall, Amber W ^a   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b DSO NATIONAL LABORATORIES   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; INFLUENZA VACCINE; LIVE VACCINE; S LIVE ATTENUATED INFLUENZA VACCINE; S TRIVALENT INACTIVATED VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SEASONAL INFLUENZA;

ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG; MICE; PANDEMICS; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

MUS; ORTHOMYXOVIRIDAE; TIPULA IRIDESCENT VIRUS;

EID: 79551617166     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1009908108     Document Type: Article

References (49)

1. Dawood FS, et al.; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360:2605-2615.
2. Garten RJ, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197-201.
3. Centers for Disease Control and Prevention (CDC) (2009) 2009 pandemic influenza A (H1N1) virus infections - Chicago, Illinois, April-July 2009. MMWR Morb Mortal Wkly Rep 58:913-918.
4. Hancock K, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361:1945-1952.
5. Kelly HA, Grant KA, Williams S, Fielding J, Smith D (2009) Epidemiological characteristics of pandemic influenza H1N1 2009 and seasonal influenza infection. Med J Aust 191:146-149.
6. Vaillant L, La Ruche G, Tarantola A, Barboza P; Epidemic Intelligence Team at InVS Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill 14:pii:19309.
7. Clark TW, et al. (2009) Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361:2424-2435.
8. Greenberg ME, et al. (2009) Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361:2405-2413.
9. Nolan T, et al. (2010) Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: A randomized trial. JAMA 303:37-46.
10. Zhu FC, et al. (2009) A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 361:2414-2423.
11. Parkman PD, Hopps HE, Rastogi SC, Meyer HM, Jr. (1977) Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 136 (Suppl):S722-S730.
12. Kelly H, Grant K (2009) Interim analysis of pandemic influenza (H1N1) 2009 in Australia: Surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 14:pii:19288.
13. Garcia-Garcia L, et al. (2009) Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: Case-control study in Mexico City. BMJ 339:b3928.
14. Echevarría-Zuno S, et al. (2009) Infection and death from influenza A H1N1 virus in Mexico: A retrospective analysis. Lancet 374:2072-2079.
15. Crum-Cianflone NF, et al. (2009) Clinical and epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. Clin Infect Dis 49:1801-1810.
16. Skowronski DM, et al. (2010) Canadian SAVOIR Team (2010) Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: Four observational studies from Canada. PLoS Med 7:e1000258.
17. Steel J, et al. (2010) Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment. J Virol 84:21-26.
18. Ge X, et al. (2010) Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol 84: 3312-3319.
19. Greenbaum JA, et al. (2009) Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 106: 20365-20370.
20. Tu W, et al. (2010) Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 84:6527-6535.
21. Del Giudice G, et al. (2009) Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci Transl Med 1:12re1.
22. Kobinger GP, et al. (2010) Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus. J Infect Dis 201:1000-1006.
23. Chen Z, et al. (2010) Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 84:44-51.
24. Murphy BR, Clements ML (1989) The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 146:107-116.
25. Forrest BD, et al. (2008) Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 15:1042-1053.
26. He XS, et al. (2006) Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 80:11756-11766.
27. Hoelscher MA, et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367:475-481.
28. Armerding D, Liehl E (1981) Induction of homotypic and heterotypic T- and B-cell immunity with influenza A virus in mice. Cell Immunol 60:119-135.
29. Loosli CG, Hamre D, Gerber P (1958) Antigenic variants of influenza A virus (PR8 strain). V. Virulence, antigenic potency, and cross-protection tests in mice of the original and second series. J Exp Med 107:857-868.
30. Laurie KL, et al. (2010) Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis 202:1011-1020.
31. Bennink J, Effros RB, Doherty PC (1978) Influenzal pneumonia: Early appearance of cross-reactive T cells in lungs of mice primed with heterologous type A viruses. Immunology 35:503-509.
32. + T cells persist in the lungs following recovery from respiratory virus infections. J Immunol 166:1813-1822.
33. Powell TJ, et al. (2007) Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol 178:1030-1038.
34. Christensen JP, Doherty PC, Branum KC, Riberdy JM (2000) Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory. J Virol 74:11690-11696.
35. + T cells for long-term pulmonary protection against influenza. Eur J Immunol 36: 770-778.
36. Jackson DC, et al. (2004) A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 101:15440-15445.
37. + cytotoxic T lymphocytes. Respir Res 8:44.
38. Taylor PM, Askonas BA (1986) Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 58:417-420.
39. Furuya Y, et al. (2010) Cytotoxic T cells are the predominant players providing crossprotective immunity induced by γ-irradiated influenza A viruses. J Virol 84:4212-4221.
40. + T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 159:5197-5200.
41. Lau YF, Santos C, Torres-Vélez FJ, Subbarao K (2011) The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines. J Virol 85:76-85.
42. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty PC (2002) Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J Virol 76: 12388-12393.
43. + T cells are ineffective in clearing a pulmonary infection with influenza type A virus in the absence of B cells. Virology 239:217-225.
44. + T cells is inefficient in the absence of B cells. J Virol 72:882-885.
45. Brown DM, Dilzer AM, Meents DL, Swain SL (2006) CD4 T cell-mediated protection from lethal influenza: Perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 177:2888-2898.
46. + T cells promote the clearance of influenza virus from major histocompatibility complex class II -/- respiratory epithelium. J Virol 70:1288-1291.
47. Crowe SR, Miller SC, Shenyo RM, Woodland DL (2005) Vaccination with an acidic polymerase epitope of influenza virus elicits a potent antiviral T cell response but delayed clearance of an influenza virus challenge. J Immunol 174:696-701.
48. Lau YF, et al. (2006) Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int Immunol 18:1801-1813.
49. Reed LJ, Muench H (1938) A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493-497.